/stocks — the workspaceLOADING
All UPC SEC filings, by type → · Earnings date & implied move · Search inside filings
UPC is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Universe Pharmaceuticals INC (UPC) is a pharmaceutical preparations company. Piotroski F-Score 4/8. Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
What’s behind UPC’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has UPC been issuing shares? Offering history →
FY ending 2025-09-30 vs 2024-09-30. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
| Free cash flow per share | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2025 | -11667.97 USD | -697916.88 USD | not a growth rate (a year at or below zero) | 20-F filed 2026-01-29 |
| fiscal 2024 | -697.92 USD | 177.52 USD | not a growth rate (a year at or below zero) | 20-F filed 2025-04-29 |
| fiscal 2023 | 0.30 USD | -0.39 USD | not a growth rate (a year at or below zero) | 20-F filed 2024-01-30 |
| fiscal 2022 | -0.06 USD | -0.13 USD | not a growth rate (a year at or below zero) | 20-F filed 2023-02-10 |
| fiscal 2021 | -0.13 USD | 0.38 USD | not a growth rate (a year at or below zero) | 20-F filed 2022-01-31 |
Concepts read: (us-gaap:NetCashProvidedByUsedInOperatingActivities - us-gaap:PaymentsToAcquirePropertyPlantAndEquipment) / us-gaap:ProfitLoss / us-gaap:EarningsPerShareBasicAndDiluted; (us-gaap:NetCashProvidedByUsedInOperatingActivities - us-gaap:PaymentsToAcquirePropertyPlantAndEquipment) / us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
| Diluted EPS | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2025 | -8.06 USD | -626.96 USD | not a growth rate (a year at or below zero) | 20-F filed 2026-01-29 |
| fiscal 2024 | -626.96 USD | -1089.21 USD | not a growth rate (a year at or below zero) | 20-F filed 2025-04-29 |
| fiscal 2023 | -1.70 USD | -2.41 USD | not a growth rate (a year at or below zero) | 20-F filed 2024-01-30 |
| fiscal 2022 | -0.40 USD | 0.60 USD | not a growth rate (a year at or below zero) | 20-F filed 2023-02-10 |
| fiscal 2021 | 0.60 USD | 0.47 USD | +27.7% | 20-F filed 2022-01-31 |
Concepts read: us-gaap:EarningsPerShareBasicAndDiluted; us-gaap:EarningsPerShareDiluted
Per filed share, as each report states it. Free cash flow per share is operating cash flow less capital expenditure, over the diluted weighted average share count (or net income over diluted EPS where the count is tagged per share class).
Each year’s change comes from one annual report, which states that year and the year before on the same share basis, and the rate compounds those changes; so a split or a restatement between reports cannot bend it. A rate needs a positive figure at both ends of its window. The DCF above grows total free cash flow and divides by today’s share count, so a per-share rate also carries the buybacks or new shares of those years. These are past figures, not a forecast.
Not shown yet: the P/E range UPC has traded at, which would set the discount rate and terminal assumptions against its own history. It needs a long daily price history we are not yet licensed to display.
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
The filed share count is 5x or more off the one filed before it, a tagging fault until shown otherwise, so it is withheld.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from UPC’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as UPC tagged it: revenue us-gaap:Revenues, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on UPC plus an auto-SWOT, built from UPC's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate UPC using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about UPC’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Group: Pharmaceutical Preparations, the SEC industry code UPC files under. 10 companies in our stored table file under it.
| Metric | UPC | Group median | 25th to 75th percentile | Where UPC sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | not placed | 21.4%⊙ |
| 13.0% to 28.4% |
| UPC has no annual report in the stored table yet, so it has no figure to place. |
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | not placed | 20.9%⊙INFERENCE — derived by arithmetic SourceFree cash flow margin across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's operating cash flow less capital expenditure, divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 16.7% to 26.7% | UPC has no annual report in the stored table yet, so it has no figure to place. |
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | not placed | 32.9%⊙INFERENCE — derived by arithmetic SourceReturn on equity across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by stockholders’ equity at the fiscal year end, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 12.5% to 38.2% | UPC has no annual report in the stored table yet, so it has no figure to place. |
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
Projected from UPC's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentUPC files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
Nothing on file for UPC from Nov 3, 2026 to Nov 16, 2026 in these sources: earnings date and filing deadline.
| Event | Result |
|---|---|
| Earnings date | nothing in the window. No date in the window: no regular report cadence in the filings. |
| Filing deadline | nothing in the window. Nothing in the window: the 20-F for the fiscal year ending Sep 30, 2026, due four months after it, falls due Feb 1, 2027, after it. Newest periodic report on file: the 20-F for the period ending Sep 30, 2025, filed Jan 29, 2026. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-03 to 2026-11-16, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
None of the 5 estimators could run on UPC's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for UPC. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for UPC, so sector medians could not fill the gaps.
Every refusal recorded for UPC → · How often we decline, and why →
Free cash flow does not currently cover the dividend. That is the single most important test here, and it failing outweighs the tests that passed.
The score is passed over computable, not passed out of five. If only three tests could be run on UPC’s filings, the score is out of three and the other two are listed with the reason they were skipped. Scoring a skipped test as a failure would punish a company for how its industry reports, and scoring it as a pass would flatter one.
Labels come from that ratio:
Below three computable tests we publish no label at all and show the individual results instead. A summary drawn from one or two tests is not a summary.
Free cash flow coverage carries the most weight in practice, because dividends are paid in cash and free cash flow is the cash actually available to pay them. The earnings payout ratio is the better-known test but the weaker one — earnings are an accounting figure, dividends are not. Where the two disagree, believe the cash.
Why tests get skipped. A REIT gets no earnings payout ratio: GAAP depreciation on appreciating property understates a REIT’s distributable earnings, which is exactly why the industry reports FFO and why REITs are required to distribute most of their taxable income. Banks and insurers get no leverage test, because deposits are debt and structurally high leverage is what a balance-sheet business is, not a warning sign.
The biggest limitation, stated plainly. The coverage tests read a single fiscal year, and one year of cash flow is far more volatile than a dividend record. A legal settlement, a tax payment or an acquisition can sink coverage in a year that says nothing about the dividend. Where a weak year contradicts a long unbroken record, we say so above rather than letting the harsher number stand alone — but you should still check what happened in that specific year.
The streak is the weakest test here, and it is deliberately listed last. Every dividend that was ever cut had an unbroken streak right up until the year it was cut. A freeze does not break the run — a company that holds its dividend flat through a bad year has not cut it — so raises are counted separately, and a long flat run cannot pass itself off as dividend growth.
Every figure above is from UPC’s own SEC filings and the arithmetic is stated on this page. This describes what the filings show about the dividend’s coverage — it is not a prediction that the dividend will or will not be cut, not a recommendation, and not investment advice. A covered dividend can still be cut, and a strained one can still be maintained for years. Educational information only.
Volume against its own history: 90% of its last 252 sessions were lighter than the last one, the 2026-11-02 session. End-of-day bars (Databento). Volume detail
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
No lawmaker has disclosed a trade in UPC under the STOCK Act.
No tracked institution reported a position in UPC in the latest 13F round.
Daily closes from 2024-07-01 through 2026-11-02, 588 sessions, split-adjusted (2 splits applied). No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in UPC’s filings; the chart with studies draws every figure.
Written by code from 588 end-of-day bars through 2026-11-02. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
Total return including reinvested dividends, from UPC’s adjusted closing prices. Past return is not a forecast and not investment advice.
No open-market Form 4 buys or sells reported for UPC in the last ~6 months.
2 of the 2 checks that ran found nothing new for UPC. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: Ji’an, Jiangxi, China · the company’s charter and its head office are in different countries.
EDGAR’s company directory says China. We show the company’s own most recent filing. The directory is a separate record, and the two can differ in either direction: a directory entry can change before the next filing shows a reincorporation, or go on showing a jurisdiction the company has left.
Source: the cover page of Universe Pharmaceuticals INC’s 20-F filed 2026-01-29, on EDGAR. Filings checked 2026-11-03. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works